Probiotics plus intensified hyperfractionated chemoradiation with adebrelimab maintenance for limited-stage small cell lung cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase 2, single-center study enrolls adults with limited-stage small cell lung cancer (ECOG 0-1) who have received no more than two rounds of chemotherapy (with or without immunotherapy). Participants receive concurrent hyperfractionated radiotherapy with a simultaneous integrated boost together with chemotherapy and daily probiotics, followed by adebrelimab monoclonal antibody as maintenance immunotherapy. The study will track tumor control, progression-free and overall survival, and treatment-related toxicities to characterize safety and activity. All treatment and follow-up are conducted at Fudan University Shanghai Cancer Center.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Sign written informed consent before implementing any experimental procedures;
2. Age range: 18-80 years old;
3. Pathological diagnosis of small cell lung cancer;
4. Limited stage;
5. ECOG PS 0-1；
6. Receive ≤ 2 rounds of chemotherapy or chemotherapy plus immunotherapy;
7. Expected survival time\>3 months;

Exclusion Criteria:

1. Progress after 2 induction treatments;
2. Severe emphysema, interstitial changes in the lungs, COPD patients;
3. Resting blood oxygen\<93;
4. Have a history of other malignant tumors and have received chemotherapy in the past 3 years;
5. History of chest radiotherapy;

Where it's running

• Fudan University Shanghai Cancer Center
  Shanghai, Shanghai Municipality, China Recruiting

Study contacts

• Study coordinator: Xingwen Fan
• Email: wenxingfan@126.com
• Phone: +86 13651669687

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Shrinkage-free combo in LS-SCLC: SHR-7787 plus SHR-1316

  This trial tests whether the combo of SHR-7787 and SHR-1316 can help adults with unresectable limited-stage small cell lung cancer after prior platinum-based chemo and radiation.

  Recruiting Phase 2 Shanghai Hengrui Pharmaceutical Co., Ltd. · Jinan, Shandong · NCT07798947

• Trilaciclib to Protect the Blood System in Limited-Stage Small Cell Lung Cancer

  This trial tests whether trilaciclib can protect blood-forming cells in people with limited-stage small cell lung cancer when given with standard therapy, compared with placebo.

  Recruiting Phase 3 Pharmacosmos A/S · Oakland, California · NCT07473128

• Tarlatamab as maintenance treatment after chemo-radiotherapy for limited-stage small-cell lung cancer.

  This trial will test whether giving tarlatamab after chemo-radiotherapy helps people with limited-stage small-cell lung cancer stay progression-free longer.

  Recruiting at 20 sites Phase 2 Fundación GECP · Albacete, Albacete and 19 other locations · NCT07242547

• Durvalumab consolidation after chemoradiation for limited-stage small-cell lung cancer in China

  This project will test durvalumab given after chemoradiation in people with limited‑stage small‑cell lung cancer who have not progressed, to see how well it works and how safe it is in routine care.

  Recruiting at 20 sites AstraZeneca · Beijing and 20 other locations · NCT07161388

• Combination therapy for limited-stage small cell lung cancer

  This study is testing a new combination of immunotherapy and chemotherapy to see if it can help people with limited-stage small cell lung cancer have better treatment results.

  Recruiting Phase 2 Shanghai Pulmonary Hospital, Shanghai, China · Shanghai · NCT06256237

• Combination treatment for extensive stage small cell lung cancer

  This study is testing a new combination treatment for people with extensive stage small cell lung cancer to see if it helps them live longer and feel better.

  Recruiting at 4 sites Phase 2 Hoosier Cancer Research Network · Indianapolis, Indiana and 3 other locations · NCT05903092

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.